Flex Pharma Announces Scientific Advisory Board Appointment and Management Change
August 26 2016 - 4:05PM
Business Wire
-- W. Larry Kenney, Ph.D., Penn State
University Professor of Physiology and Kinesiology, Joins
Scientific Advisory Board --
-- Kathie Lindemann, COO, Continues Leading
Consumer; Marina Hahn Transitions to Advisor --
Click to Tweet
Flex Pharma, Inc. (NASDAQ: FLKS) announced today that W. Larry
Kenney, Ph.D., Professor of Physiology and Kinesiology at Penn
State University, has joined the Company’s Scientific Advisory
Board. In addition, the Company announced today that Marina Hahn
has transitioned from President, Consumer to become an advisor to
the Company. Ms. Lindemann, Chief Operating Officer (COO), will
continue to lead the Company’s consumer business for which she
assumed operational responsibility in May 2016 in anticipation of
the Company’s launch of HOTSHOT™, the first scientifically proven
product to prevent and treat exercise associated muscle cramps.
Flex Pharma is a biotechnology company developing innovative and
proprietary treatments for nocturnal leg cramps (NLC), spasms
associated with severe neuromuscular conditions such as multiple
sclerosis (MS) and amyotrophic lateral sclerosis (ALS), and
exercise-associated muscle cramps (EAMC).
“Dr. Kenney is a recognized leader in the field of exercise
physiology,” noted Bruce Bean, Ph.D., Harvard Medical School
Professor of Neurophysiology, Flex Pharma Co-founder and Scientific
Advisory Board Co-Chair. “Larry will add an important new
perspective to the Flex Pharma Scientific Advisory Board as we
advance our thinking about cramps and motor performance in healthy
athletes.”
As the Marie Underhill Noll Chair in Human Performance and
Professor of Physiology and Kinesiology at Penn State University,
Dr. Kenney is focused on research involving human physiological
responses and adaptations to exercise and extreme environments. He
is lead author of Physiology of Sport and Exercise, a best-selling
textbook now in its 6th edition, and has published more than 200
journal articles and book chapters. Dr. Kenney served as President
of the American College of Sports Medicine from 2003-2004. He
serves on the American Council of Exercise Scientific Advisory
Panel, Nike’s Science Advisory Board, and chaired the Gatorade®
Sports Science Institute for several years. Dr. Kenney received his
Ph.D. in Physiology from Penn State.
“We thank Marina for her great contributions that formed the
creative vision for HOTSHOTTM, a unique product and brand,” said
Christoph Westphal, M.D., Ph.D., Chair and CEO of Flex Pharma. “We
are pleased that we will have continued access to Marina’s
expertise as the Company moves into this next phase of the rollout
of HOTSHOTTM.”
Kathie Lindemann joined Flex in August 2015 as COO. Prior to
joining Flex Pharma, Ms. Lindemann served as COO at DAVIDsTEA Inc.
Ms. Lindemann also spent 19 years at Starbucks where she held
several leadership roles including Senior Vice President, Starbucks
Foodservice, SVP US Business Operations, and SVP International
Operations, Store Development and Global Business Systems.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for nocturnal leg cramps,
cramps and spasms associated with severe neuromuscular conditions
such as MS and ALS, and exercise-associated muscle cramps. Flex
Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D.,
recognized leaders in the fields of ion channels and neurobiology,
along with Chair and CEO Christoph Westphal, M.D., Ph.D.
Visit www.TeamHOTSHOT.com for updates and to learn more about
HOTSHOTTM, the Company’s consumer product which is scientifically
proven to prevent and treat muscle cramps.
HOTSHOTTM is a consumer product that is marketed to endurance
athletes for exercise-associated muscle cramps. HOTSHOTTM
complements the Company’s drug development business and is not
intended to diagnose, treat, cure or prevent any disease.
Follow Flex Pharma (@flexpharma) and HOTSHOTTM (@Team_HOTSHOT)
on Twitter
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the management of our consumer business and our plans to
commercialize our consumer products. These forward-looking
statements are based on management's expectations and assumptions
as of the date of this press release and are subject to numerous
risks and uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation: our
ability to commercialize our consumer products; anticipated
positioning and product attributes of our consumer products; other
matters that could affect the availability or commercial potential
of our consumer product; the inherent uncertainties associated with
intellectual property; and other factors discussed in greater
detail under the heading "Risk Factors" in our Annual Report on
Form 10-K for the year ended December 31, 2015 and subsequent
filings with the Securities and Exchange Commission (SEC). You are
encouraged to read our filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and
uncertainties. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160826005687/en/
Flex Pharma, Inc.Elizabeth Woo, 617-874-1829SVP, Investor
Relations & Corporate Communicationsirdept@flex-pharma.com
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Jun 2024 to Jul 2024
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Jul 2023 to Jul 2024